PRRT Plus Pembrolizumab Confers Durable Disease Control in Well-Differentiated NETs
PRRT and pembrolizumab provided durable disease control in a trial of patients with well-differentiated NETs.
Related Articles
FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.
Harnessing Family Connections to Prevent Hereditary Cancers : Oncology Times
An abstract is unavailable.
Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management
Kari Wisinski, MD, highlights treatments for HER2– breast cancer, the role of chemotherapy in TNBC, and the benefits of T-DXd for brain metastases.
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer
Nature Cancer – Yang et al. show that transcription–replication collisions lead to large tandem duplications, which are frequent in female-enriched, upper gastrointestinal tract and prostate…
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma
Key PointsLong-lasting cytopenia after BCMA CAR-T therapy correlates with baseline cytopenia and peak inflammatory markers.Supernatants from activated BCMA
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.
An Overview of HER2 Alterations in NSCLC and Implications for Treatment
Panelists discuss how understanding the distinctions between HER2 overexpression and mutations in NSCLC influences patient care strategies and prognosis, alongside the challenges of biomarker testing…
IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors
The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,
Advances in oncolytic immunotherapy for melanoma: vusolimogene oderparepvec
Gino In, MD, University of Southern California, Los Angeles, CA, comments on the potential of oncolytic immunotherapies for the treatment of advanced melanoma. The Phase…
Tandem Meetings Home
The Tandem Meetings are a premier event in the evolving hematopoietic cell transplantation (HCT) and cellular therapy field. Through the scientific program, attendees gain access…
